All In Biotech

Drug Trial Radar · NCT07479576

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

A Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2106 vs Tremfye® in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Nov 10, 2025

Primary completion

Apr 23, 2026

Study completion Apr 23, 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2106 versus Tremfye®(Guselkumab) in healthy subjects after a single dose.

Conditions

  • Healthy Participants

Interventions

  • QL2106Drug

    100mg/1 ml; single dose; subcutaneous injection

  • Tremfye®Drug

    100mg/1 ml; single dose; subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics EndpointTime frame: 0-113 days
  2. Pharmacokinetics EndpointTime frame: 0-113 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.